Faraday Pharmaceuticals, Inc.

We will soon be headed to the windy city for #ACC25 to meet with medical experts and thought leaders in the field of STEMI. Please stop by booth 2053 to learn more about our pivotal Phase 3 clinical trial, #IocyteAMI3, assessing the efficacy and safety of #FDY_5301 in reducing the incidence of cardiovascular death and heart failure in anterior STEMI patients undergoing primary PCI.

Our Faraday team members had a productive 2 days at #ACVC2025. If you missed us, we will be at #ACC25 in Chicago later this month. This May, you will find us in Washington DC for #SCAI2025, and Paris for #EuroPCR.

With #ACVC2025 underway, we are looking forward to reconnecting with colleagues and forming new relationships. Please visit us at stand A2 to learn about #IocyteAMI3, a Phase 3 clinical trial assessing the efficacy and safety of #FDY_5301 in reducing the incidence of cardiovascular death and heart failure in anterior STEMI patients undergoing primary PCI.

The Association for Acute CardioVascular Care annual congress brings together healthcare professionals from a variety of disciplines with a common interest in acute and critical care of cardiovascular disease. Visit us at Stand A2 to learn how Faraday is targeting ischemia-reperfusion injury to reduce cardiac damage and heart failure. #ACVC2025

A recent review article by Andrea Mignatti et. al. in Journal of Clinical Medicine (JCM) MDPI mentions FDY-5301 as a novel pharmacological strategy for potentially limiting reperfusion injury in STEMI-PCI patients. #FDY_5301 #IocyteAMI3 Link to this open access article:?https://lnkd.in/gGPtmCNd

Faraday‘s pivotal Iocyte AMI-3 study continues on target for a Q4 2025 readout. All randomized patients have passed through the 6-month timepoint, and will complete the 12-month follow-up by Q3 of this year. #IocyteAMI3 #faradaypharma #FDY_5301

Faraday Pharmaceuticals to Present at Oppenheimer & Co. Inc. 35th Annual Healthcare Life Sciences Conference See the full press release https://lnkd.in/grjkcSCa #faradaypharma #IocyteAMI3 #FDY_5301

Our Faraday team members had a productive day 1 at #ASHP24. Please visit us at booth #1928 to learn how Faraday is targeting ischemia-reperfusion injury to reduce cardiac damage and heart failure.

Our team is looking forward to joining ASHP at #ASHP24 in New Orleans! Find us in Booth 1928 to learn how Faraday is targeting ischemia-reperfusion injury to reduce cardiac damage and heart failure. #FDY_5301 #IocyteAMI3

Faraday Pharmaceuticals to Participate in Jefferies London Healthcare Conference. See the full press release https://lnkd.in/gyxBM_Wi #faradaypharma #IocyteAMI3 #FDY_5301 #JefferiesHealthcare